<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600002</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 02-69</org_study_id>
    <secondary_id>2003-2972</secondary_id>
    <nct_id>NCT00600002</nct_id>
  </id_info>
  <brief_title>Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Nelson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The application of immunotherapeutic strategies that target the most potent antigen&#xD;
      presenting cell, the dendritic cell (DC), are likely to substantially increase the magnitude&#xD;
      of the anti-tumor immune response. Although there are issues of activation state and antigen&#xD;
      load, mechanisms to increase the number of DCs available to the immune system are among the&#xD;
      first steps in development of affective DC based immunotherapeutic strategies. The Central&#xD;
      Hypothesis of our study is: Administration of Granulocyte Macrophage Colony Stimulating&#xD;
      Factor (GM-CSF) to patients with pancreatic adenocarcinoma will result in enhance recruitment&#xD;
      of DCs to the sentinel lymph node, into the peripheral blood, and/or tumor site. We propose&#xD;
      performing a phase I, dose escalation, clinical trial of systemic and intra-tumoral GM-CSF&#xD;
      administration for the treatment of pancreatic adenocarcinoma. This trial will be designed to&#xD;
      assess toxicity and immunologic effects, principally dendritic cell recruitment. Patients&#xD;
      with resectable pancreatic adenocarcinoma by clinical staging criteria will be eligible for&#xD;
      enrollment.&#xD;
&#xD;
      The trial we propose is a phase I clinical trial of the addition of GM-CSF as a biological&#xD;
      adjuvant to standard care for patients with potentially resectable pancreatic adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate toxicity, dendritic cell recruitment, and immune parameters</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to treatment failure</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate biochemical markers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Resectable Pancreatic Adenocarcinoma</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.</description>
    <arm_group_label>GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histological proven adenocarcinoma of the pancreas with potentially&#xD;
             resectable disease based upon clinical staging.&#xD;
&#xD;
          -  Expected survival must be greater than three (3) months.&#xD;
&#xD;
          -  A Karnofsky Performance Status (KPS) must be 70 or greater.&#xD;
&#xD;
          -  Patients must be &gt;18 years of age. Because LeukineÂ® is a &quot;Pregnancy Category C&quot; drug,&#xD;
             female patients must be not be lactating and must be surgically sterile (via&#xD;
             hysterectomy or bilateral tubal ligation), postmenopausal, or using acceptable methods&#xD;
             of contraception if they are of child bearing potential. Female patients of&#xD;
             childbearing potential must also have a negative serum pregnancy test.&#xD;
&#xD;
          -  Patients must be able to understand and sign an informed consent form, which must&#xD;
             comply with U.S. regulations (U.S. 21 Code of Federal Regulations (CFR) 50) and&#xD;
             International Conference on Harmonisation (ICH) guidelines. Availability of&#xD;
             alternative curative treatment must be fully explained to the patient and documented&#xD;
             in the informed consent form.&#xD;
&#xD;
          -  Eligible patients must meet the following laboratory parameters:&#xD;
&#xD;
          -  White blood cell (WBC) &gt;3,000/mm3&#xD;
&#xD;
          -  Platelets &gt;100,000/mm3&#xD;
&#xD;
          -  Hct &gt;33% or Hgb &gt;10.5 gm/dL&#xD;
&#xD;
          -  Prothrombin time (PT) within 3 seconds of control&#xD;
&#xD;
          -  Serum creatinine &lt;1.5 mg/dL&#xD;
&#xD;
          -  Serum calcium &lt;11.0 mg/dL&#xD;
&#xD;
          -  Serum Amylase &lt; 2 times the upper limit of normal&#xD;
&#xD;
          -  Negative HIV-Ag and HIV-Ab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have undergone previous treatment with a biological response modifier&#xD;
             (interferons, interleukins) or prior immunotherapy within four (4) weeks of study&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients currently requiring corticosteroids, under immune suppression for any reason&#xD;
             including an organ allograft.&#xD;
&#xD;
          -  Patients with known contraindications to analgesia or endoscopy.&#xD;
&#xD;
          -  Patients with unstable cardiovascular disease (Class IV cardiovascular disease&#xD;
             according to the New York Heart Association's functional criteria).&#xD;
&#xD;
          -  Patients with any acute or chronic illness as judged clinically significant by the&#xD;
             Investigators.&#xD;
&#xD;
          -  Patients who have received prior chemotherapy or radiation therapy to the thorax&#xD;
             within four (4) weeks of enrollment.&#xD;
&#xD;
          -  Prior surgery within 30 days of execution of the informed consent form.&#xD;
&#xD;
          -  Persistent fever greater than 39 degrees Celsius unless clinical assessment attributes&#xD;
             the etiology to be tumor.&#xD;
&#xD;
          -  Primary malignancy (present or remote) of sites other than the pancreas, except for&#xD;
             the basal cell epithelioma of the skin.&#xD;
&#xD;
          -  Use of investigational drugs within 30 days of execution of the informed consent form.&#xD;
&#xD;
          -  Clinically significant (symptomatic) third space fluid collection (i.e.: ascites,&#xD;
             pleural effusion).&#xD;
&#xD;
          -  Patients with a diagnosis of an autoimmune state, or any psychiatric illness that in&#xD;
             the opinion of the Investigators would compromise treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward L Nelson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>June 7, 2018</last_update_submitted>
  <last_update_submitted_qc>June 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Edward Nelson</investigator_full_name>
    <investigator_title>Dr. Edward Nelson</investigator_title>
  </responsible_party>
  <keyword>GM-CSF</keyword>
  <keyword>Leukine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

